[go: up one dir, main page]

WO2017208174A3 - Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de pfkfb3 - Google Patents

Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de pfkfb3 Download PDF

Info

Publication number
WO2017208174A3
WO2017208174A3 PCT/IB2017/053209 IB2017053209W WO2017208174A3 WO 2017208174 A3 WO2017208174 A3 WO 2017208174A3 IB 2017053209 W IB2017053209 W IB 2017053209W WO 2017208174 A3 WO2017208174 A3 WO 2017208174A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
subject
pfkfb3
administering
treating disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/053209
Other languages
English (en)
Other versions
WO2017208174A2 (fr
Inventor
Slavica TUDZAROVA-TRAJKOVSKA
Peter C. Butler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2017208174A2 publication Critical patent/WO2017208174A2/fr
Publication of WO2017208174A3 publication Critical patent/WO2017208174A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés de traitement d'une maladie liée au mauvais repliement des protéines chez un sujet, les procédés comprenant l'administration d'au sujet un inhibiteur de PFKFB3. D'autres aspects concernent un procédé de traitement ou de prévention de la mort cellulaire induite par le mauvais repliement des protéines dans une cellule, le procédé comprenant l'administration d'un inhibiteur de PFKFB3 à la cellule. L'invention concerne également des procédés d'inhibition ou de réduction de la mort de cellules β chez un sujet souffrant de diabète de type 2, le procédé comprenant l'administration d'un inhibiteur de PFKFB3 au sujet.
PCT/IB2017/053209 2016-05-31 2017-05-31 Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de pfkfb3 Ceased WO2017208174A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662343377P 2016-05-31 2016-05-31
US62/343,377 2016-05-31

Publications (2)

Publication Number Publication Date
WO2017208174A2 WO2017208174A2 (fr) 2017-12-07
WO2017208174A3 true WO2017208174A3 (fr) 2018-02-01

Family

ID=60479205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/053209 Ceased WO2017208174A2 (fr) 2016-05-31 2017-05-31 Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de pfkfb3

Country Status (1)

Country Link
WO (1) WO2017208174A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021007101A2 (pt) * 2018-10-15 2021-07-27 Gero Discovery Limited Liability Company composto, composto para uso como neuroprotetor, sal de adição de ácido farmaceuticamente aceitável, derivado, n-óxido, solvato, tautômero, estereoisômero, racemato, sal fisiologicamente aceitável, composição farmacêutica, composições farmacêuticas neuroprotetiva e antienvelhecimento, meio tangível, agente de deleção, diminuição, ligação, inibição ou degradação de pfkfb3, inibidores de pfkfb3, de pfkfb3 para uso em neuroproteção, de atividade de quinase de pfkfb3 de molécula pequena, de atividade de quinase de pfkfb3, de molécula pequena de pfkfb3 e de molécula pequena de atividade de quinase de pfkfb3, kits para tratamento de um quadro mediado por pfkfb3 e/ou pfkfb4, de um câncer, para tratamento antienvelhecimento e para neuroproteção, métodos de imunossupressão e para tratamento de um câncer, de tumor sólido, de um câncer hematológico, de um câncer ósseo, de osteosarcoma, de doença, de isquemia cerebral, de derrame isquêmico neonatal, de insulto neurológico, de derrame isquêmico, de envelhecimento acelerado de sobrevivente de câncer, de envelhecimento acelerado de indivíduo sofrendo de hiv, de uma lesão traumática no cérebro, de um indivíduo humano após lesão no sistema nervoso central aguda, para o tratamento de um transtorno associado à modulação de níveis f-2,6-p2 em um mamífero, para tratamento ou prevenção de um transtorno ou doença relacionada à idade ou outro tratamento antienvelhecimento e para prevenção ou tratamento de consequências da quimioterapia e da radioterapia, para tratamento ou profilaxia de doença ou quadro no qual a inibição de glicólise tem efeito benéfico, de doença neurodegenerativa ou quadro no qual a inibição de glicólise tem efeito benéfico e de doença neurodegenerativa ou quadro neurodegenerativo, para intensificar o efeito de tratamento de câncer por radiação, o efeito de tratamento de câncer ósseo por radiação e o efeito de tratamento de osteosarcoma por radiação, para reduzir a capacidade de as células cancerosas repararem seu dna e reduzir inflamação aterosclerótica e/ou pelo menos uma de suas consequências clínicas, para sensibilizar a célula cancerosa para a terapia citostática e/ou de radiação, e, métodos para neuroproteção, para fabricação de uma medicação, para fabricação de uma medicação de neuroproteção, para aumento de capacidade antioxidante de célula, para reduzir uma absorção glicolítica no neurônio, para prevenção de morte apoptótica do neurônio, para reduzir uma absorção glicolítica no astrócito, para inibição reativa à proliferação de astrócito, para proteção de um neurônio contra a excitotoxicidade, para proteção de um neurônio entérico contra a excitotoxicidade, para atenuação ou prevenção de dano neuronal em um indivíduo humano, para prevenção ou tratamento de doença relacionada ao envelhecimento, para melhoria de um parâmetro, para rejuvenescimento, para radioproteção, para a mudança de biomarcador ou biomarcadores de mortalidade, para a mudança de biomarcador ou biomarcadores de longevidade ou
CN116096891A (zh) * 2020-07-10 2023-05-09 雀巢产品有限公司 包含mir-3184的营养组合物
JP2023538612A (ja) * 2020-08-18 2023-09-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 糖尿病治療及びベータ細胞再生のための方法及び組成物
JP2024518003A (ja) * 2021-05-16 2024-04-23 メタノイア バイオ インコーポレイテッド 心血管疾患を治療するための方法及び組成物
US20240269124A1 (en) * 2021-05-16 2024-08-15 Metanoia Bio Inc. Methods and compositions for treating neurological conditions
US20250074989A1 (en) * 2021-05-16 2025-03-06 Metanoia Bio Inc. Methods and compositions for treating pancreatic disease
CN115851793A (zh) * 2022-09-23 2023-03-28 龙岩学院 一种高效表达猪pfkfb3基因的真核表达载体及其构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074884A1 (en) * 2007-06-18 2009-03-19 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074884A1 (en) * 2007-06-18 2009-03-19 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
LUOTO ET AL.: "Tumor hypoxia as a driving force in genetic instability", GENOME INTEGR., vol. 4, no. 1, 2013, pages 5, XP021166963 *
MUKHERJEE ET AL.: "Type 2 diabetes as a protein misfolding disease", TRENDS MOL MED., vol. 21, no. 7, 2015, pages 439 - 49, XP055459655 *
SALABEI ET AL.: "Type 2 Diabetes Dysregulates Glucose Metabolism in Cardiac Progenitor Cells", J BIOL CHEM., vol. 291, no. 26, 2016, pages 13634 - 48, XP055459653 *
WANG ET AL.: "Protein misfolding in the endoplasmic reticulum as a conduit to human disease", NATURE, vol. 529, no. 7586, January 2016 (2016-01-01), pages 326 - 35, XP055459666 *
WU ET AL.: "From acute ER stress to physiological roles of the Unfolded Protein Response", CELL DEATH DIFFER., vol. 13, no. 3, March 2006 (2006-03-01), pages 374 - 84, XP055459659 *
YADAV ET AL.: "Endoplasmic Reticulum Stress and Cancer", J CANCER PREV., vol. 19, no. 2, 2014, pages 75 - 88, XP055459647 *

Also Published As

Publication number Publication date
WO2017208174A2 (fr) 2017-12-07

Similar Documents

Publication Publication Date Title
WO2017208174A3 (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de pfkfb3
PH12020551205A1 (en) Fap inhibitors
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018010374A (es) Inhibidores del enlace proteína-proteína de wdr5.
PH12018502507B1 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
HK1245677A1 (zh) 用於治疗炎症和癌症的杂环itk抑制剂
WO2015023976A3 (fr) Inhibiteurs sélectifs de la grp94 et leurs utilisations
EA201791576A1 (ru) Ингибитор jak
WO2012064897A3 (fr) Inhibiteurs bicyliques et tricycliques d'enzymes de sumoylation et leurs procédés d'utilisation
BR112016015236A8 (pt) composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença.
WO2014031928A3 (fr) Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
WO2015077540A3 (fr) Compositions et procédés de traitement de l'hypertension pulmonaire
JOP20180094A1 (ar) مركب حلقي غير متجانس كمثبط بروتين كيناز
WO2017019540A3 (fr) Inhibiteurs de glycosylation à liaison en n et procédés les utilisant
WO2012125981A3 (fr) Inhibiteurs des kinases raf
BR112018071467A2 (pt) método de tratamento ou prevenção de patologias hepáticas
WO2014186450A3 (fr) Inhibiteurs très puissants de porc-épic
WO2016004404A3 (fr) Inhibiteurs de gls1 utiles pour le traitement de maladies
WO2013169631A3 (fr) Inhibiteurs de la signalisation par la protéine wnt
EA201692038A1 (ru) Способы и композиции для лечения сосудистой мальформации
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
HK1246685A1 (zh) 治疗或预防具有心肌梗塞病史的患者的动脉粥样硬化血栓形成事件的方法
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
NZ727715A (en) Novel heterocyclic compounds having prs enzyme inhibitory effect
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17805989

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17805989

Country of ref document: EP

Kind code of ref document: A2